

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




FIG.1

Malignant Breast  
96102003G H9C65



FIG.2A

Malignant Breast  
9609C033R H9C65




FIG.2B

Normal Breast.  
9712C030G H9C65




FIG.2C

MB8 Cell Line  
H9C65




FIG.2D

Malignant Breast  
96102003G H95C30




FIG.3A

Malignant Breast  
9609C033R H95C30




FIG.3B

Normal Breast  
9712C030G H95C30



FIG.3C

MB8 Cell Line  
H95C30





FIG.3D


4/25

1 2 3 4 1




anti-mycMAb  
**FIG.4A**

1 2 3 4 2



anti-BU101 PAb 10923  
**FIG.4B**

5/25




anti-Mam PAb 10931

FIG.4C

6/25



**FIG.5A**



**FIG.5B**

7/25

1 2 3 4  
1 2 1 2 1 2

10918 10923 11543 10931

**FIG.6A**


5 6 7 8  
1 2 1 2 1 2 1 2

H85 H68 H111 myc

**FIG.6B**

8/25

9 10 11 12  
1 2 1 2 1 2 1 2




10918 10923 11543 10931

Polyclonal Antisera, 1:5000

**FIG. 6C**

13 14 15 16  
1 2 1 2 1 2 1 2



H85 H68 H111 myc

Monoclonal Antibodies 1:50

**FIG. 6D**

9/25


1 2



FIG.7


10/25

1 12  
24  
36  
48  
60  
72  
84



**FIG.8A**

1 12  
24  
36  
48  
60  
72  
84



**FIG.8B**

11/25




FIG.9

12/25





FIG.10

13/25

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15




**FIG.11A**

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15




**FIG.11B**

14/25



anti-BU101.3, 10923, 1:5000  
sample reduced and boiled

**FIG. 12A**




anti-MAM.1, 10931, 1:5000  
sample reduced and boiled

**FIG. 12B**

## Reduced

Not Reduced

42 43 44 45 46 47 48 42 43 44 45 46 47 48



**Polyclonal Antibody 10923**  
**anti-BU101.3**

FIG. 13A

16/25

Reduced	Not Reduced
42 43 44 45 46 47 48	42 43 44 45 46 47 48



Polyclonal Antibody 10931  
anti-MAM.1


**FIG. 13B**

17/25



anti-BU101 polyclonal 10923


**FIG.14A**



anti-Mam polyclonal

**FIG.14B**

18/25



anti-myc, 1:5000

FIG. 15

Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys Cys  
1 5 10 15  
Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu Leu  
20 25 30  
Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala Lys  
35 40 45  
Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys Arg  
50 55 60  
Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu Val  
65 70 75 80  
Leu Val Lys Ile Leu Lys Lys Cys Ser Val  
85 90

FIG.16

## ASSEMBLY OF BS106 FROM INDIVIDUAL EXPRESSED TAGS




FIG.17

>BS106 CONSENSUS

CGGCTCGAGCTTCTAGGCTTGAAGCATTTGTCTGTGCTCCCT  
GATCTTCAGGTCAACCACCATGAAGTTCTTAGCAGTCCTGGTACTC  
TTGGGAGTTCCATCTTCTGGTCTCTGCCAGAACATCCGACAACA  
GCTGCTCCAGCTGACACGTATCCAGCTACTGGTCTGCTGATGAT  
GAAGCCCCCTGATGCTGAAACCACTGCTGCTGCAACCACCGCGACC  
ACTGCTGCTCCTACCACTGCAACCAACCGCTGCTTCTACCACTGCT  
CGTAAAGACATTCCAGTTACCCAAATGGGTTGGGATCTTCCG  
AATGGTAGAGTGTGTCCTGAGATGGAATCAGCTTGAGTCTTCTG  
CAATTGGTCACAACATTATGCTTCTGTGATTTCATCCAACTA  
CTTACCTTGCCCTACGATATCCCCTTATCTCTAATCAGTTTATT  
TCTTCAAATAAAAAATAACTATGAGCAACATAAAAAAAAAAAA

FIG. 18A

>BS106 TRANSLATION

MKFLAVLVLLGVSIFLVSAQNPTTAAPADTPATGPADDEAPDAE  
TTAAATTATTAAPTTATTAASTTARKDIPVLPKVGDLPNGRVCP

FIG. 18B

22/25




FIG.19A




FIG.19B





FIG.19C


1 2 3 4 5 6 7 8 9 10 11 12



Anti-BU101.3 Polyclonal

**FIG.20A**


1 2 3 4 5 6 7 8 9 10 11 12



Anti-Mam.1 Polyclonal

**FIG.20B**


208 kD →  
105 kD →  
53 kD →  
34 kD ↘  
23 kD ↘  
17 kD ↘  
13 kD ↘  
7 kD →



Anti-BU101.3 Polyclonal

FIG.20C

208 kD →  
105 kD →  
53 kD →  
34 kD ↘  
23 kD ↘  
17 kD ↘  
13 kD ↘  
7 kD →



Anti-Mam.1 Polyclonal

FIG.20D

Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mammaglobin	CK19
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)
ER	-0.18 NS	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)
PR	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)
HER2	-0.12 (NS)	<b>0.36 (p=0.003)</b>	0.11 (NS)	0.02 (NS)
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS)
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)
Mamm	<b>0.37 (p=0.0001)</b>	<b>0.004 (NS)</b>	-----	0.07 (NS)

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. NS=not significant

FIG. 21